Modulating epigenetic modifications for cancer therapy (Review)
Open Access
- 10 February 2023
- journal article
- review article
- Published by Spandidos Publications in Oncology Reports
- Vol. 49 (3) , 1-23
Abstract
Cancer is a global public health concern. Alterations in epigenetic processes are among the earliest genomic aberrations occurring during cancer development and are closely related to progression. Unlike genetic mutations, aberrations in epigenetic processes are reversible, which opens the possibility for novel pharmacological treatments. Non‑coding RNAs (ncRNAs) represent an essential epigenetic mechanism, and emerging evidence links ncRNAs to carcinogenesis. Epigenetic drugs (epidrugs) are a group of promising target therapies for cancer treatment acting as coadjuvants to reverse drug resistance in cancer. The present review describes central epigenetic aberrations during malignant transformation and explains how epidrugs target DNA methylation, histone modifications and ncRNAs. Furthermore, clinical trials focused on evaluating the effect of these epidrugs alone or in combination with other anticancer therapies and other ncRNA‑based therapies are discussed. The use of epidrugs promises to be an effective tool for reversing drug resistance in some patients with cancer.Keywords
This publication has 252 references indexed in Scilit:
- Molecular Mechanisms of Long Noncoding RNAsMolecular Cell, 2011
- Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphomaThe Journal of Antibiotics, 2011
- KAT(ching) Metabolism by the Tail: Insight into the Links between Lysine Acetyltransferases and MetabolismChemBioChem, 2010
- A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 ResponseCell, 2010
- Role of HDAC1 in senescence, aging, and cancerExperimental Gerontology, 2010
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- MicroRNA biogenesis: coordinated cropping and dicingNature Reviews Molecular Cell Biology, 2005
- Mechanisms of gene silencing by double-stranded RNANature, 2004